Federated Hermes Inc. Sells 61,570 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Federated Hermes Inc. trimmed its holdings in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 7.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 787,747 shares of the company's stock after selling 61,570 shares during the quarter. Federated Hermes Inc. owned 1.70% of Omnicell worth $35,070,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of OMCL. Wells Fargo & Company MN grew its position in Omnicell by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 132,252 shares of the company's stock worth $5,888,000 after purchasing an additional 28,390 shares during the last quarter. ExodusPoint Capital Management LP lifted its stake in shares of Omnicell by 120.5% in the fourth quarter. ExodusPoint Capital Management LP now owns 88,974 shares of the company's stock valued at $3,961,000 after buying an additional 48,623 shares during the period. Bryce Point Capital LLC acquired a new stake in Omnicell during the fourth quarter worth about $492,000. Huntington National Bank grew its position in Omnicell by 236.4% during the fourth quarter. Huntington National Bank now owns 1,359 shares of the company's stock worth $61,000 after buying an additional 955 shares in the last quarter. Finally, Headlands Technologies LLC bought a new position in Omnicell during the fourth quarter valued at about $53,000. Institutional investors and hedge funds own 97.70% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on OMCL. Benchmark reissued a "buy" rating and set a $62.00 price objective on shares of Omnicell in a report on Tuesday, February 4th. Wells Fargo & Company decreased their price target on shares of Omnicell from $49.00 to $40.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. StockNews.com cut shares of Omnicell from a "buy" rating to a "hold" rating in a research note on Monday, March 24th. Bank of America decreased their target price on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a research report on Monday, January 6th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research report on Thursday, March 20th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $51.00.

Omnicell Price Performance

Shares of Omnicell stock traded up $0.11 during mid-day trading on Friday, reaching $31.19. 566,792 shares of the stock were exchanged, compared to its average volume of 529,438. Omnicell, Inc. has a fifty-two week low of $25.12 and a fifty-two week high of $55.75. The firm has a 50-day simple moving average of $36.34 and a 200 day simple moving average of $41.67. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The company has a market cap of $1.46 billion, a price-to-earnings ratio of 115.52, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, sell-side analysts predict that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.